Dr. Sharman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
520 Country Club Pkwy
Eugene, OR 97401Phone+1 541-683-5001Fax+1 541-684-8029- Is this information wrong?
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2005 - 2008
Massachusetts General HospitalResidency, Internal Medicine, 2001 - 2004
University of California, Davis, School of MedicineClass of 2001
Certifications & Licensure
CA State Medical License 2004 - Present
OR State Medical License 2008 - 2025
MA State Medical License 2003 - 2006- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
- Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
- MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
- Join now to see all
Publications & Presentations
PubMed
- Six-year update of the ELEVATE-TN study on acalabrutinib.Jeff Sharman> ;Clinical Advances in Hematology & Oncology. 2024 Apr 1
- Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.Xu, L., Shadman, M., Flinn, I., Levy, M., Porter, R., Burke, J., Zafar, S., Cultrera, J., Misleh, J., Kingsley, E., Yimer, H., Freeman, B., Chaudhry, A., Tumula, P., G...> ;Haematologica. 2024 Jan 25
- 1 citationsConsensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy.Jennifer L Crombie, Tara Graff, Lorenzo Falchi, Yasmin H Karimi, Rajat Bannerji, Loretta J Nastoupil, Catherine Thieblemont, Renata Ursu, Nancy L Bartlett, Victoria R ...> ;Blood. 2024 Jan 22
- Join now to see all
Journal Articles
- An Open‐Label Phase 2 Trial of Entospletinib in Indolent Non‐Hodgkin Lymphoma and Mantle Cell LymphomaJeff P Sharman, David J Andorsky, Christopher A Yasenchak, Kathryn S Kolibaba, British Journal of Haematology
- IdelalisibFurhman, New England journal
Abstracts/Posters
- Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analys...Jeff P. Sharman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Evolution in Practice Patterns and Differences Among Experts and Community Healthcare Providers in the Treatment of Patients with Chronic Lymphocytic LeukemiaJeff P. Sharman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible BrutonÍS Tyrosine Kinase Inhibitor, Vecabrutinib, ...Jeff P. Sharman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Final Results from the Multicenter, Open-Label, Phase II GIBB Study of Obinutuzumab+Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Indolent Lymphomas: The Marathon Has a New Course61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Join now to see all
Press Mentions
CALQUENCE plus Obinutuzumab Demonstrated Sustained Survival Benefit in 1st-Line Chronic Lymphocytic Leukemia with 90% of Patients Surviving Five Years in ELEVATE-TN TrialJune 4th, 2022- Triplet Regimen Steps up as Potential First-Line CLL TherapyNovember 18th, 2021
- AstraZeneca’s Calquence Showed Improvement in Small Group of Hospitalized COVID-19 PatientsJune 5th, 2020
- Join now to see all
Other Languages
- Spanish
Hospital Affiliations
- McKenzie-Willamette Medical CenterSpringfield, Oregon
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
